Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMIRIS: Ramucirumab plus FOLFIRI vs Ramucirumab plus Paclitaxel in Gastric/GEJ Adenocarcinoma
2024-512934-14-00Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of ramucirumab, irinotecan, fluorouracil, folinic acid and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Overall survival and Objective overall response rate. Started Nov 2024; status: completed.
02
Drugs
ramucirumabirinotecanfluorouracilfolinic acidpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-512934-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512934-14-00.